These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2070286)

  • 41. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy.
    Steurer G; Weber H; Schmidinger H; Plass H; Frey B; Pürerfellner H; Probst P
    Eur Heart J; 1991 Apr; 12(4):526-32. PubMed ID: 2065687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Propafenone--a new agent for the treatment of ventricular arrhythmias.
    Grubb BP
    Am J Med Sci; 1989 Oct; 298(4):249-51. PubMed ID: 2679087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Solitary beta-blocker therapy for idiopathic life-threatening ventricular tachyarrhythmias.
    Brodsky MA; Sato DA; Allen BJ; Chesnie BM; Henry WL
    Chest; 1986 Jun; 89(6):790-4. PubMed ID: 2872017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short- and long-term effects of propafenone in ventricular arrhythmias.
    Gaita F; Richiardi E; Bocchiardo M; Asteggiano R; Pinnavaia A; Di Leo M; Rosettani E; Brusca A
    Int J Cardiol; 1986 Nov; 13(2):163-70. PubMed ID: 3793276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prevalence of proarrhythmic events during moricizine therapy and their relationship to ventricular function.
    Tschaidse O; Graboys TB; Lown B; Lampert S; Ravid S
    Am Heart J; 1992 Oct; 124(4):912-6. PubMed ID: 1529903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in cardiac output determined by continuous-wave Doppler echocardiography during propafenone or mexiletine drug testing.
    Lange H; Lampert S; Sutton MS; Lown B
    Am J Cardiol; 1990 Feb; 65(7):458-62. PubMed ID: 2305684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate.
    Scanu P; Grollier G; Guilleman D; Iselin M; Bustany P; Hurpe JM; Potier JC
    Pacing Clin Electrophysiol; 1991 May; 14(5 Pt 1):783-6. PubMed ID: 1712954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.
    Lombardi F; Torzillo D; Sandrone G; Dalla Vecchia L; Finocchiaro ML; Bernasconi R; Cappiello E
    Am J Cardiol; 1992 Oct; 70(11):1028-34. PubMed ID: 1357951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Propafenone Poisoning of a Female Adolescent After a Suicide Attempt.
    Keramari S; Poutoglidis A; Poutoglidou F; Kaiafa G; Keramaris M
    Cureus; 2021 Jul; 13(7):e16576. PubMed ID: 34434676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Propafenone-induced peripheral neuropathy.
    Galasso PJ; Stanton MS; Vogel H
    Mayo Clin Proc; 1995 May; 70(5):469-72. PubMed ID: 7731257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exacerbation of myasthenia by propafenone.
    Lecky BR; Weir D; Chong E
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):377. PubMed ID: 2056335
    [No Abstract]   [Full Text] [Related]  

  • 52. Propafenone associated agranulocytosis.
    Miwa LJ; Jolson HM
    Pacing Clin Electrophysiol; 1992 Apr; 15(4 Pt 1):387-90. PubMed ID: 1374882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ventricular Tachycardia in Association with Propafenone Overdose.
    Kim HK; Kim SS; Ki YJ; Park KH; Choi DH
    Acta Cardiol Sin; 2021 Jan; 37(1):100-103. PubMed ID: 33488033
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to "Ventricular Tachycardia in Association with Propafenone Overdose" by Hyun Kuk Kim.
    Trebach J; Mohan S; Hoffman RS
    Acta Cardiol Sin; 2021 May; 37(3):324. PubMed ID: 33976520
    [No Abstract]   [Full Text] [Related]  

  • 55. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM; Palmer KJ; Langtry HD; Fitton A
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Propafenone in the treatment of patients with malignant ventricular tachyarrhythmias.
    Kowey PR; Stohler JL; Friehling TD; Marinchak RA
    Can J Cardiol; 1991 May; 7(4):175-80. PubMed ID: 2070286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Malignant ventricular arrhythmias in the subacute and late phases of myocardial infarction. Clinical arrhythmological characteristics and prognostic value].
    Proclemer A; Facchin D; Fresco C; Bernardi G; Fontanelli A; Feruglio GA
    G Ital Cardiol; 1990 May; 20(5):400-11. PubMed ID: 2210161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.
    van Wijk LM; Crijns HJ; Kingma HJ; van Gilst WH; van Gelder IC; Wesseling H; Lie KI
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):884-91. PubMed ID: 1694910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.